Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient and at least one pyrazolo pyridine derivative according to Formula (I):
wherein: G 1 is H;
G 2 is optionally substituted phenyl;
G 3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 4 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 5 is H; or pharmaceutically acceptable salts, tautomers, geometrical isomers, optically active forms, enantiomers, diastereomers and racemate forms thereof.
2. The pharmaceutical composition according to claim 1 , wherein G 2 is selected from phenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-nitrophenyl, 2-chlorophenyl, 2-methyl phenyl, 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 2,5-difluorophenyl and 2-methoxyphenyl.
3. The pharmaceutical composition according to claim 1 , wherein G 3 is optionally substituted alkyl.
4. The pharmaceutical composition according to claim 1 , wherein G 3 is methyl.
5. The pharmaceutical composition according to claim 1 , wherein G 3 is optionally substituted phenyl.
6. The pharmaceutical composition according to claim 1 , wherein G 4 is selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.
7. The pharmaceutical composition according to claim 1 , wherein G 4 is selected from optionally substituted aryl alkyl and optionally substituted heteroaryl alkyl.
8. The pharmaceutical composition according to claim 1 , wherein G 4 is selected from optionally substituted morpholinyl alkyl, optionally substituted piperazinyl alkyl, optionally substituted pyrrolidinyl alkyl and optionally substituted tetrahydrofuranyl alkyl.
9. The pharmaceutical composition according to claim 1 , wherein G 4 is selected from optionally substituted morpholinyl propyl, optionally substituted morpholinyl ethyl, optionally substituted piperazinyl ethyl, optionally substituted pyrrolidinyl propyl and optionally substituted tetrahydrofuranyl methyl.
10. The pharmaceutical composition according to claim 1 , wherein said pyrazolo pyridine derivative is selected from:
4-methyl-2-phenyl-5-(thiophen-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-(furan-2-ylmethyl)-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-phenyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-phenyl-5-(2-phenylethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-[2-(1H-indol-3-yl)ethyl]-4-methyl-1-(3-methylbenzyl)-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
1-(4-fluorobenzyl)-5-[2-(1H-indol-3-yl)ethyl]-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
1-(2-chlorobenzyl)-4-methyl-5-[3-(2-oxopyrrolidin-1-yl)propyl]-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
1-(4-chlorobenzyl)-5-[2-(1H-imidazol-4-yl)ethyl]-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-(1,3-benzodioxol-5-ylmethyl)-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-benzyl-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-benzyl-2-(4-fluorophenyl)-4-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-benzyl-2-(4-methoxyphenyl)-4-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-benzyl-4-methyl-2-(4-nitrophenyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-phenyl-5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-[2-(1H-indol-3-yl)ethyl]-4-methyl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-5-morpholin-4-yl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-5-(2-morpholin-4-ylethyl)-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-morpholin-4-yl-2-phenyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2,4-diphenyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-ethyl-5-(pyridin-3-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethyl)phenyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethoxy)phenyl]-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; and
4-ethyl-2-(2-methoxyphenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, tautomers, geometrical isomers, optically active forms, enantiomers, diastereomers and racemate forms.
11. A method of preparing a pharmaceutical composition comprising combining a pyrazolo pyridine derivative according to Formula (I):
wherein:
G 1 is H;
G 2 is optionally substituted phenyl;
G 3 is selected from H optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 4 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 5 is H;
or pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable carrier, excipient or diluent.
12. A method for the treatment of a patient suffering from a disease or condition selected from the group consisting of diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds, hyperactive bladder, liver fibrosis, alcohol induced fibrosis, steatosis, non-alcoholic steatohepatitis, bronchial asthma, bronchitis, allergic rhinitis, adult respiratory syndrome, viral lung infection, pulmonary hypertension, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, erectile dysfunction, fertility disorders, prostatic hypertrophy, benign prostatic hypertrophy, pain, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelium sarcoma, lymphangiosarcoma, lymphangioendothelioma, periosteoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostatic carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, orchioncus, lung cancer, small-cell lung cancer, bladder cancer, epithelial cancer, gastric mucosa disorders, ischemic bowel disease management, enteritis/colitis, cancer chemotherapy, neutropenia, a disease or a state characterized by a central nervous system (CNS) degeneration or alteration, and arthritis, comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier, diluent or excipient and at least one pryazolo pyridine derivative according to Formula (I):
wherein:
G 1 is H;
G 2 is optionally substituted phenyl;
G 3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 4 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 5 is H; or pharmaceutically acceptable salts, tautomers, geometrical isomers, optically active forms, enantiomers, diastereomers and racemate forms thereof, to a patient in need of treatment of said disease or condition.
13. The method according to claim 12 , wherein said disease or disorder is selected from diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds and hyperactive bladder.
14. The method according to claim 12 , wherein said disease or disorder is selected from liver fibrosis, alcohol induced fibrosis, steatosis and non-alcoholic steatohepatitis.
15. The method according to claim 12 , wherein said disease or disorder is selected from bronchial asthma, bronchitis, allergic rhinitis, adult respiratory syndrome, viral lung infection pulmonary hypertension and chronic obstructive pulmonary diseases (COPD).
16. The method according to claim 12 , wherein said disease or disorder is pulmonary fibrosis.
17. The method according to claim 12 , wherein said disease or disorder is selected from erectile dysfunction, fertility disorders, prostatic hypertrophy and benign prostatic hypertrophy.
18. The method according to claim 12 , wherein said pain is an inflammatory pain.
19. The method according to claim 12 , wherein said disease or condition is selected from the group consisting of fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelium sarcoma, lymphangiosarcoma, lymphangioendothelioma, periosteoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostatic carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, broncho genic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, orchioncus, lung cancer, small-cell lung cancer, bladder cancer and epithelial cancer.
20. The method according to claim 12 , wherein said disease or disorder is selected from the group consisting of gastric mucosa disorders, ischemic bowel disease management, enteritis/colitis, cancer chemotherapy, and neutropenia.
21. The method according to claim 12 , wherein said disease or disorder is a disease or a state characterized by a central nervous system (CNS) degeneration or alteration.
22. The method according to claim 12 , wherein said disorder or disease is arthritis.
23. A pyrazolo pyridine derivative according to Formula (I):
wherein:
G 1 is H;
G 2 is optionally substituted phenyl;
G 3 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally subtituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optional substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally substituted alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionall substituted C 3 -C 8 -cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted G 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 4 is selected from H, optionally substituted alkyl, optionally substituted alkenyl, alkynyl, optionally substituted aryl, optionally substituted alkyl aryl, optionally substituted aryl alkyl, optionally substituted heteroaryl, optionally substituted alkyl heteroaryl, optionally substituted heteroaryl alkyl, optionally substituted alkenyl aryl, optionally substituted aryl alkenyl, optionally alkenyl heteroaryl, optionally substituted heteroaryl alkenyl, optionally substituted C 3 -C 8 -cycloalkyl, heterocycloalkyl, optionally substituted alkyl C 3 -C 8 -cycloalkyl, optionally substituted C 3 -C 8 -cycloalkyl alkyl, optionally substituted alkyl heterocycloalkyl and optionally substituted heterocycloalkyl alkyl;
G 5 is H,
and said pyrazolo pyridine derivative is selected from:
5-benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo[4,3c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-{1,3-benzothiazol-2-yl)-4-methyl-1-(pyridin-2-ylmethyl)-5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H}-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl)1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1yl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethyl)phenyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; or
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; and pharmaceutically acceptable salts, tautomers, geometrical isomers, optically active forms, enantiomers, diastereomers and racemate forms thereof.
24. A method for the treatment of a patient suffering from a disease or condition selected from the group consisting of diabetic nephropathy, renal failure, glomerulonephritis, nephrotoxicity of aminoglycosides and platinum compounds, hyperactive bladder, liver fibrosis, alcohol induced fibrosis, steatosis, non-alcoholic steatohepatitis, bronchial asthma, bronchitis, allergic rhinitis, adult respiratory syndrome, viral lung infection, pulmonary hypertension, chronic obstructive pulmonary diseases (COPD), pulmonary fibrosis, erectile dysfunction, fertility disorders, prostatic hypertrophy, benign prostatic hypertrophy, pain, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelium sarcoma, lymphangiosarcoma, lymphangioendothelioma, periosteoma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostatic carcinoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocellular carcinoma, cholangiocarcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, orchioncus, lung cancer, small-cell lung cancer, bladder cancer, epithelial cancer, gastric mucosa disorders, ischemic bowel disease management, enteritis/colitis, cancer chemotherapy, neutropenia, a disease or a state characterized by a central nervous system (CNS) degeneration or alteration and arthritis, comprising administering a compound selected from:
benzyl-4-ethyl-2-(4-fluorophenyl)-1H-pyrazolo[4,3c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1 H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
2-{1,3-benzothiazol-2-yl)-4-methyl-1-(pyridin-2-ylmethyl)5-(tetrahydrofuran-2-ylmethyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H}-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4ylpropyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1yl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione;
4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1H-pyrazolo[4,3-c]pyridine-3,6 (2H,5H)-dione;
5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1H-pyrazolo[4,3c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethyl)phenyl)-1H-pyrazolo [4,3-c]pyridine-3,6(2H,5H)-dione;
4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethoxy)phenyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; or
2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione; and pharmaceutically acceptable salts, tautomers, geometrical isomers, optically active forms, enantiomers, diastereomers and racemate forms thereof, to a patient in need of treatment of said disease or condition.
25. The method according to claim 21 , wherein said patient is treated for a disease or a state characterized by a central nervous system (CNS) degeneration or alteration at the neuronal level.
26. The method according to claim 24 , wherein said patient is treated for a disease or a state characterized by a central nervous system (CNS) degeneration or alteration at the neuronal level.
27. The method according to claim 24 , wherein said patient is treated for a viral lung infection caused by influenza.
28. The method according to claim 12 , wherein said patient is treated for a viral lung infection caused by influenza.